Scope of judicial review under Article 226: supervisory, not appellate; factual reappraisal barred, challenge dismissed; insolvency professional dutie...
Courier transshipment of imported goods via named carrier to air cargo stations renewed until 30.01.2026; exemption conditional, strict controls apply...
Insurer's investment gains and investment write-downs face Section 263 revision; enquiry upheld, Rule 5(b)(ii) lapse sustained, late corrigendum quash...
Page of 4817
Press 'Enter' after typing page number.
7241 to 7260 of 96333 Results
❮
❯
❯❯
0 / 200
Expand Note
Add to Folder
No Folders have been created
+
Are you sure you want to delete "My most important" ?
Deduction for capital expenditure on scientific research under...
Pre-commencement R&D deduction denied where business had not commenced; deeming benefit requires tangible start of manufacture or commercial exploitation.
Contents
Summary
Note
Bookmark
Share
✓ Copied successfully !
Print
Print Options
For full text, please login
Login to TaxTMI
Verification Pending
The Email Id has not been verified. Click on the link we have sent on
Deduction for capital expenditure on scientific research under section 35(1)(iv) is subject to the deeming rule only where the taxpayer has in fact commenced the business that will exploit the R&D; the deeming benefit for expenditure in the three years prior hinges on an ascertainable start of manufacture or commercial exploitation. The Tribunal held that absence of purchases, sales, closing stock, and only capital work in progress and unbilled dossier revenue showed no commencement; it allowed the Revenue's appeal, reversed the CIT(A) and upheld the AO's disallowance for AY 2018 19.
Deduction for capital expenditure on scientific research under section 35(1)(iv) is subject to the deeming rule only where the taxpayer has in fact commenced the business that will exploit the R&D; the deeming benefit for expenditure in the three years prior hinges on an ascertainable start of manufacture or commercial exploitation. The Tribunal held that absence of purchases, sales, closing stock, and only capital work in progress and unbilled dossier revenue showed no commencement; it allowed the Revenue's appeal, reversed the CIT(A) and upheld the AO's disallowance for AY 2018 19.
Note: It is a system-generated summary and is for quick reference only.